dermatology lesions

Tools and Technologies for More Objective Dermatology Clinical Trials

From the reliance on visual assessments to the lack of a consensus on instruments for assessment and monitoring, there are many causes for this subjectivity concern. However, there are a variety of tools and technologies available that can help make this process more objective.

FDA IND Submissions, Novella Clinical

What You Need to Know About Submitting an IND to the FDA

As the nation’s principal authority overseeing the safety of food, drugs and cosmetics, the US Food and Drug Administration (FDA) requires manufacturers to provide proof of the safety and efficacy of their drugs before bringing them to market. This has … Read More

Biologics, Novella Clinical

Biologics Market in Dermatology: Promise for the Future?

The age of biologics in the treatment of dermatological indications is upon us. They hold promise for dermatological indications where treatments have been sparse. An increased demand for solutions to dermatological conditions where biologics might be effective can be attributed to several factors: increase in incidence of skin cancers, breakthroughs in biologics for psoriasis, and boomer generation demand for anti-aging products.